Advertisement

Qualität der Arzneimittelversorgung

  • Ulrich Schwabe

Zusammenfassung

Die Qualität der Arzneimittelversorgung ist in den letzten Jahren bei vielen großen Volkskrankheiten durch Einsatz innovativer Medikamente erheblich verbessert worden. Bei Patienten mit Tumorschmerzen, Diabetes und Epilepsie war im Jahr 2001 bundesweit praktisch eine Vollversorgung gewährleistet. Bei der Sekundärprophylaxe der koronaren Herzkrankheit mit Statinen wird das Ziel voraussichtlich in diesem Jahr erreicht werden. Bei der Depression ist die Zahl der Antidepressivaverordnungen in den letzten zehn Jahren fast verdoppelt worden. Patienten mit multipler Sklerose werden in Deutschland häufiger als in den USA und in Großbritannien mit Betainterferonen behandelt. Lediglich bei der Alzheimerdemenz entspricht die Arzneitherapie bisher nicht den heutigen Möglichkeiten, da hier noch viele veraltete Mittel ohne nachweisbaren Nutzen eingesetzt werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ashburn M.A., Staats P.S. (1999): Management of chronic pain. Lancet 353: 1865–1869.PubMedCrossRefGoogle Scholar
  2. Bell J.R. (1997): Australian trends in opioid prescribing for chronic non-cancer pain, 1986–1996. Med. J. Aust. 167: 26–29.PubMedGoogle Scholar
  3. Bellach B.M., Knopf H., Thefeld W. (1998): The German Health Survey. 1997/98. Gesundheitswesen 60 (Suppl. 2): S59–S68.PubMedGoogle Scholar
  4. Bernabei R., Gambassi G., Lapane K., Landi F., Gatsonis C., Dunlop R. et al. for the SAGE Study Group (1998): Management of pain in elderly patients with cancer. JAMA 279: 1877–1882.Google Scholar
  5. Bickel H. (2000): Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany. Gesundheitswesen 62: 211–218.PubMedCrossRefGoogle Scholar
  6. Bono A.V., Cuffari S. (1997): Effectiveness and tolerance of tramadol in cancer patients. A comparative study with respect to buprenorphine. Drugs 53 (Suppl. 2): 40–49.PubMedCrossRefGoogle Scholar
  7. Breivik H. (2001): Opioids in cancer and chronic non-cancer pain therapy — indications and controversies. Acta Anaesthesiol. Scand. 45: 1059–1066.Google Scholar
  8. Caldwell J.R., Hale M.E., Boyd R.E., Hague J.M., Iwan T., Shi M., Lacouture P.G. (1999): Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J. Rheumatol. 26: 862–869.PubMedGoogle Scholar
  9. Collett B.-J. (2001): Chronic opioid therapy for non-cancer pain. Brit. J. Anaesth. 87: 133–143.PubMedCrossRefGoogle Scholar
  10. Cosentino M., Leoni O., Banfi F., Lecchini S., Frigo G. (2000): An approach for the estimation of drug prescribing using the defined daily dose methodology and drug dispensation data. Eur. J. Clin. Pharmacol. 56: 513–517.PubMedCrossRefGoogle Scholar
  11. Davis M.P., Walsh D. (2001): Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9: 73–83.PubMedCrossRefGoogle Scholar
  12. Diabetes Prevention Program Research Group (2002): Reduction in the incidence of type 2 diabetes wit lifestyle intervention or metformin. N. Engl. J. Med. 346: 393–403.CrossRefGoogle Scholar
  13. Draeger K.E., Wernicke-Panten K., Lomp H.-J., Schüler E., Roßkamp R. (1996): Longterm treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryr): a double-blind comparison with glibenclamide. Horm. Metab. Res. 28: 419–425.PubMedCrossRefGoogle Scholar
  14. Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., Schneider R.L. for the Pioglitazone 027 Study Group (2000): Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin. Ther. 22: 1395–1409.CrossRefGoogle Scholar
  15. Fonseca V., Rosenstock J., Patwardhan R., Salzman A. (2000): Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 283: 1695–1702.PubMedCrossRefGoogle Scholar
  16. Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohlfs J.L. (1997): Efficacy of metformin in type 11 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. 103: 491–497.PubMedCrossRefGoogle Scholar
  17. Hagen N.A., Babul N. (1997): Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 79: 1428–1437.PubMedCrossRefGoogle Scholar
  18. Heidemann E. (1999): Tumorpatienten in Deutschland: Was wissen wir über Schmerzprävalenzen? Schmerz 13: 249–252.PubMedCrossRefGoogle Scholar
  19. Hein T., Hopfenmüller W. (2000): Hochrechnung der Zahl an Multipler Sklerose erkrankten Patienten in Deutschland. Nervenarzt 71: 288–294.PubMedCrossRefGoogle Scholar
  20. Holman R.R., Turner R.C., Cull C.A. on behalf of the UKPDS Study Group (1999): A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22: 960–964.CrossRefGoogle Scholar
  21. Horton E.S., Foley J., Clinkingbeard C., Mallows S., Gatlin M., Shen S. (2000): Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23: 1660–1665.PubMedCrossRefGoogle Scholar
  22. Hufnagel A., Noachtar S. (1998): Epilepsien und ihre medikamentöse Behandlung. In: Brandt T., Dichgans J., Diener H.C. (Hrsg.): Therapie und Verlauf neurologischer Erkrankungen. 3. Aufl., Kohlhammer, Stuttgart, Berlin, Köln, S. 179–203.Google Scholar
  23. Johnston P.S., Krol A., Feig P.U., Davidson J.A., Coniff R.F., Haffner S.M. (1998): Long-term titrated-dose a-glucosidase inhibition in non-insulin requiring hispanic NIDDM patients. Diabetes Care 21: 409–415.PubMedCrossRefGoogle Scholar
  24. Kappos L., Polman C., Pozzilli C., Thompson A., Beckmann K., Dahlke F., and the European Study Group in Interferon p-lb in Secondary-Progressive MS (2001): Final analysis of the European multicenter trial on IFNß-lb in secondary-progressive MS. Neurology 57: 1969–1975.CrossRefGoogle Scholar
  25. Landgraf R., Scriba P.C. (1998): Diabetes mellitus. In: ClassenM., Diehl V., Kochsiek K. (Hrsg.): Innere Medizin, 4. Aufl., Urban & Schwarzenberg, München, Wien, Baltimore, S. 895–924.Google Scholar
  26. Liebl A., Neiß A., Spannheimer A., Reitberger U., Wagner T., Görtz A. (2001): Kosten des Typ-2-Diabetes in Deutschland. Ergebnisse der CODE-r-Studie. Dtsch. Med. Wschr. 126: 585–589.PubMedCrossRefGoogle Scholar
  27. Marbury T., Huang W.-C., Strange P., Lebovitz H. (1999): Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43: 155–166.CrossRefGoogle Scholar
  28. Mayor S. (2001): Health department to fund interferon beta despite institute’s ruling. Brit. Med. J. 323: 1087.PubMedCrossRefGoogle Scholar
  29. McQuay H.J., Tramer M., Nye B.A., Carroll D., Wiffen P.J., Moore R.A. (1996): A sys- tematic review of antidepressants in neuropathic pain. Pain 68: 217–227.PubMedCrossRefGoogle Scholar
  30. Mercadante S., Casuccio A., Agnello A., Serretta R., Calderone L., Barresi L. (1998): Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J. Clin. Oncol. 16: 3656–3661.PubMedGoogle Scholar
  31. Moulin D.E., lezzi A., Amireh R., Sharpe W.K., Boyd D., Merskey H. (1996): Randomised trial of oral morphine for chronic non-cancer pain. Lancet 347: 143–147.PubMedCrossRefGoogle Scholar
  32. Muijsers R. B., Wagstaff A.J. (2001): Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 61: 2289–2307.PubMedCrossRefGoogle Scholar
  33. Munzinger H., Horstkotte E., Hoffmann W. (2001): Opioidanalgetika in der Behandlung ambulanter Tumorpatienten 1993 and 1996. Schmerz 15: 26–32.PubMedCrossRefGoogle Scholar
  34. National Institute for Clinical Excellence (2001): Beta interferon and glatiramer acetate for the treatment of multiple http://www.sclerosis.nice.org.uk.
  35. Paty D.W., Li D.K. B., the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group (1993): Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. Neurology 43: 662–667.CrossRefGoogle Scholar
  36. Portenoy R.K., Lesage P. (1999): Management of cancer pain. Lancet 353: 1695–1700.PubMedCrossRefGoogle Scholar
  37. Sabatowski R., Arens E.R., Waap I., Radbruch L. (2001): Tumorschmerztherapie in Deutschland. Ergebnisse and Analysen einer Befragung von Ärzten. Schmerz 15: 241–247.PubMedCrossRefGoogle Scholar
  38. Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.Google Scholar
  39. Schade D.S., Jovanovic L., Schneider J. (1998): A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J. Clin. Pharmacol. 38: 636–641.PubMedCrossRefGoogle Scholar
  40. Taylor D. (2001): Funding medicines for people with multiple sclerosis. Brit. Med. J. 323: 1379–1380.PubMedCrossRefGoogle Scholar
  41. Thefeld W. (1999): Prävalenz des Diabetes mellitus in der erwachsenen Bevölkerung Deutschlands. Gesundheitswesen 61 (Sonderheft 2): S85–S89.PubMedGoogle Scholar
  42. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., for the Finnish Diabetes Prevention Study Group (2001): Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344: 1343–1350.CrossRefGoogle Scholar
  43. U.K. Prospective Diabetes Study (UKPDS) Group (1998): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabdtes (UKPDS 33). Lancet 352: 837–853.CrossRefGoogle Scholar
  44. Verband Forschender Arzneimittelhersteller (2000): Die Budgets provozieren Unterversorgung. Pressemitteilung Nr. 10/2000 vom 26.6. 2000.Google Scholar
  45. Warfield C.A. (1998): Controlled-release morphine tablets in patients with chronic cancer pain. Cancer 82: 2299–2306.PubMedCrossRefGoogle Scholar
  46. Watson C.P., Babul N. (1998): Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50: 1837–1841.PubMedCrossRefGoogle Scholar
  47. WHO Collaborating Centre for Drug Statistics Methodology (2001): Guidelines for ATC classification and DDD assignment, 4th ed., Oslo, Norway.Google Scholar
  48. Wiesner G., Grimm J., Bittner E. (1999): Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Prävalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen 61 (Sonderheft 2): S72–S78.PubMedGoogle Scholar
  49. Wittchen H.U., Hofler M., Meister W. (2001): Prevalence and recognition of depressive syndromes in German primary care settings: poorly recognized and treated ? Int. Clin. Psychopharmacol. 16: 121–135.PubMedCrossRefGoogle Scholar
  50. Zech D.F., Grond S., Lynch J., Hertel D., Lehmann K.A. (1995): Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63: 65–76.PubMedCrossRefGoogle Scholar
  51. Zenz M. (2001): Zu schön, um wahr zu sein. Arzneimittelverordnungs-Report bescheinigt Deutschland Vollversorgung beim Tumorschmerz. Schmerz 15: 409–410.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Ulrich Schwabe

There are no affiliations available

Personalised recommendations